Skip to main content

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

Publication ,  Journal Article
Straus, DJ; Johnson, JL; LaCasce, AS; Bartlett, NL; Kostakoglu, L; Hsi, ED; Schöder, H; Hall, NC; Jung, S-H; Canellos, GP; Schwartz, LH ...
Published in: Blood
May 19, 2011

To reduce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leukemia Group B conducted a phase 2 trial of doxorubicin, vinblastine, and gemcitabine for newly diagnosed, nonbulky stages I and II Hodgkin lymphoma. Ninety-nine assessable patients received 6 cycles of doxorubicin 25 mg/m(2), vinblastine 6 mg/m(2), and gemcitabine 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 patients (72.7%) and partial remission in 24 of 99 patients (24.2%). The CR rate was 81% when using PET criteria. Two patients have died of Hodgkin lymphoma progression. Median follow-up for nonprogressing patients is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for patients with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and -positive patients was 88% and 54%, respectively (P = .0009), compared with 89% and 27% for cycle 6 PET-negative and -positive patients (P = .0001). Although the CR rate and PFS were lower than anticipated, patients with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

May 19, 2011

Volume

117

Issue

20

Start / End Page

5314 / 5320

Location

United States

Related Subject Headings

  • Young Adult
  • Vinblastine
  • Remission Induction
  • Prognosis
  • Positron-Emission Tomography
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Straus, D. J., Johnson, J. L., LaCasce, A. S., Bartlett, N. L., Kostakoglu, L., Hsi, E. D., … Cancer and Leukemia Group B, . (2011). Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood, 117(20), 5314–5320. https://doi.org/10.1182/blood-2010-10-314260
Straus, David J., Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, et al. “Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.Blood 117, no. 20 (May 19, 2011): 5314–20. https://doi.org/10.1182/blood-2010-10-314260.
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19;117(20):5314–20.
Straus, David J., et al. “Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.Blood, vol. 117, no. 20, May 2011, pp. 5314–20. Pubmed, doi:10.1182/blood-2010-10-314260.
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung S-H, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD, Cancer and Leukemia Group B. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19;117(20):5314–5320.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

May 19, 2011

Volume

117

Issue

20

Start / End Page

5314 / 5320

Location

United States

Related Subject Headings

  • Young Adult
  • Vinblastine
  • Remission Induction
  • Prognosis
  • Positron-Emission Tomography
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Immunology
  • Humans